We demonstrate that disrupting OSM signaling attenuates disease in MPN and AML models, establishing OSM as a central mediator linking oncogenic signaling to the inflammatory TME and unveiling a promising therapeutic target. This evidence concerns the gene OSM and myeloproliferative neoplasm.